• news.cision.com/
  • Lipidor/
  • Lipidor AB licence agreement grants Menarini Group company, RELIFE Srl, exclusive rights to register, promote, distribute and market two new psoriasis drug candidates for potential value of MEUR 70

Lipidor AB licence agreement grants Menarini Group company, RELIFE Srl, exclusive rights to register, promote, distribute and market two new psoriasis drug candidates for potential value of MEUR 70

Report this content

STOCKHOLM, Sweden, 30 June 2021: Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announced today that it has signed a licence agreement under which Lipidor grants RELIFE S.r.l., part of leading international pharmaceutical company, Menarini Group, exclusive rights to register, promote, distribute, and market drug candidates for the treatment of psoriasis in EU, Turkey, UK, Switzerland, CIS, and Balkan countries. The total potential value of this agreement is up to MEUR 70.

Under the terms of this agreement, RELIFE S.r.l., a clinical dermatology therapeutics and aesthetic medicine company, shall register, promote, distribute and market Lipidor’s drug candidates for the treatment of psoriasis in EU, Turkey, UK, Switzerland, CIS, and Balkan countries whilst Lipidor will be eligible to receive milestone payments of up to MEUR 19 and a volume-based royalty plan leading up to teens digit values on sales.

Lipidor and RELIFE S.r.l. shall collaborate to make the two topical drug candidates available for the treatment of mild to moderate psoriasis. Positive results from the Phase III study of one drug candidate, based exclusively on calcipotriol, have demonstrated that Lipidor's AKVANO® technology works well in the treatment of psoriasis. The preclinical studies carried out by Lipidor also show that betamethasone works well with AKVANO®, a positive requirement for the second drug candidate which combines calcipotriol and betamethasone. Results from the Phase III study of this second candidate, currently in its initial stages, are expected for the first half of 2022.

Lipidor’s partner Aurena Laboratories, one of the company’s two large industrial owners, will be responsible for the commercial production of the products.

“We are proud to announce that we have signed this exclusive licence agreement with RELIFE S.r.l. The Menarini Group has a strong European and global presence, and this agreement marks a step forward for Lipidor. We are looking forward to working with RELIFE and to being able to make these new candidate drugs available to psoriasis patients in the hope that they may improve the treatment of their condition,” commented Ola Holmlund, CEO of Lipidor.

“We consider this licence agreement with Menarini Group as an acknowledgement of just how committed staff and founders of Lipidor are. We hope that it shall put our company in a position whereby our proprietary and patented drug delivery AKVANO® technology may receive an even greater and stronger form of commercial validation. This agreement encourages us to bolster our efforts to create added value for our shareholders based on the AKVANO® platform through regional licensing deals for these drug candidates, and through additional innovative projects already in our pipeline,” stated Fredrik Sjövall, Chairman of the Board of Lipidor.

“We are pleased to undertake this agreement with Lipidor, a company with experience in drug formulation within the field of dermatology and psoriasis, and we are confident that the longstanding experience of Menarini Group as a trustworthy, reliable and strategic partner shall facilitate a successful product launch in the future and make the two new candidate drugs available to physicians and dermatologists for the benefit of those psoriasis patients who have to manage their condition on a  daily basis,” commented by Mr. Attilio Di Gaudio, Global Operations Director of RELIFE S.r.l., a Menarini Group company.

This disclosure contains information that Lipidor is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 01-07-2021 21:05 CET.

For more information, please contact

Ola Holmlund, CEO
Phone: +46 72 50 70 369
E-mail: ola.holmlund@lipidor.se

Certified Adviser

Erik Penser Bank AB
Telefon: +46 (0)8 463 83 00


AKVANO® is an innovative water-free and sprayable technology for the formulation of drugs and is particularly suitable for local application to, for example, the skin. AKVANO® is made up of carefully selected lipids which, together with a volatile solvent, constitute carriers of selected active substances. By combining different lipids, AKVANO® can be optimized to achieve the desired function of active components in the formulation. When applied to the skin, the solvent evaporates and a thin lipid layer is formed on the skin surface for effective release of the active substance.

About psoriasis

Psoriasis is a common, hereditary, chronic, non-contagious skin disease with no clear cause or cure. The negative impact of the disease on people's lives can be enormous. Psoriasis affects people of all ages and countries. In Sweden, it is estimated that approximately 250,000 to 300,000 individuals have psoriasis. Commonly reported prevalence of psoriasis ranges from 1 % to 5 %, making psoriasis a serious global problem with at least 100 million individuals affected worldwide. The disease can occur at any age and is most common in the 50-69 age group. Psoriasis has an unpredictable course of symptoms, a number of external triggering causes and significant comorbidity such as arthritis, cardiovascular diseases, metabolic syndrome, inflammatory bowel disease and depression. Sources: Swedish Psoriasis Association, WHO Global Report on Psoriasis 2016.

About Lipidor

Lipidor AB (publ) (www.lipidor.se) is a Swedish, Stockholm-based research and development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The Company develops topical medical products for the treatment of diseases such as psoriasis, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances.

About Menarini Group

Menarini Group is a leading international pharmaceutical company, headquartered in Italy, with a presence in 140 countries and a direct presence in over 70. The Group’s global platform extends throughout Europe, the U.S., Central America, Africa, the Middle East and Asia Pacific, and generates over $4.2 billion in annual sales. For over 130 years, Menarini has been investing in the development, production, and distribution of pharmaceuticals to serve patients and physicians around the world with a full portfolio of products covering a number of different therapeutic areas.
For further details please see www.menarini.com


RELIFE S.r.l. is a Menarini Group company that believes in a patient-centered and science-based approach to clinical dermatology therapeutics. The vision of RELIFE is to become a world leading research-based dermatology and aesthetic medicine company. https://www.relifecompany.com/ii/en/dermatology